SV2002000294A - Pirido [2,3-d] pirimidin-2,7-diaminas inhibidores de cinasas ref. pca 84-01-ca/20131/bb - Google Patents

Pirido [2,3-d] pirimidin-2,7-diaminas inhibidores de cinasas ref. pca 84-01-ca/20131/bb

Info

Publication number
SV2002000294A
SV2002000294A SV2001000294A SV2001000294A SV2002000294A SV 2002000294 A SV2002000294 A SV 2002000294A SV 2001000294 A SV2001000294 A SV 2001000294A SV 2001000294 A SV2001000294 A SV 2001000294A SV 2002000294 A SV2002000294 A SV 2002000294A
Authority
SV
El Salvador
Prior art keywords
replaced
group
po3r13r14
compounds
lower rent
Prior art date
Application number
SV2001000294A
Other languages
English (en)
Spanish (es)
Inventor
Richard John Booth
Ellen Myra Dobrusin
Yosyula Vara Prased Venkata Nagendra
Dennis Joseph Mcnamara
Peter Laurence Toogood
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of SV2002000294A publication Critical patent/SV2002000294A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
SV2001000294A 2000-01-25 2001-01-24 Pirido [2,3-d] pirimidin-2,7-diaminas inhibidores de cinasas ref. pca 84-01-ca/20131/bb SV2002000294A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25

Publications (1)

Publication Number Publication Date
SV2002000294A true SV2002000294A (es) 2002-07-16

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000294A SV2002000294A (es) 2000-01-25 2001-01-24 Pirido [2,3-d] pirimidin-2,7-diaminas inhibidores de cinasas ref. pca 84-01-ca/20131/bb

Country Status (34)

Country Link
EP (1) EP1254137A1 (is)
JP (1) JP4047010B2 (is)
KR (1) KR20020065939A (is)
CN (1) CN1395578A (is)
AP (1) AP2002002586A0 (is)
AR (1) AR030044A1 (is)
AU (1) AU2542501A (is)
BG (1) BG106850A (is)
BR (1) BR0107751A (is)
CA (1) CA2397961C (is)
CO (1) CO5261549A1 (is)
CR (1) CR6706A (is)
CZ (1) CZ20022475A3 (is)
DZ (1) DZ3266A1 (is)
EA (1) EA200200643A1 (is)
EE (1) EE200200405A (is)
GT (1) GT200100016A (is)
HN (1) HN2001000013A (is)
HU (1) HUP0204141A3 (is)
IL (1) IL150545A0 (is)
IS (1) IS6443A (is)
MA (1) MA26868A1 (is)
MX (1) MXPA02007221A (is)
NO (1) NO20023527L (is)
OA (1) OA12161A (is)
PA (1) PA8510701A1 (is)
PE (1) PE20011066A1 (is)
PL (1) PL356802A1 (is)
SK (1) SK10632002A3 (is)
SV (1) SV2002000294A (is)
TN (1) TNSN01014A1 (is)
WO (1) WO2001055147A1 (is)
YU (1) YU50402A (is)
ZA (1) ZA200205879B (is)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
ATE521353T1 (de) 2000-10-23 2011-09-15 Glaxosmithkline Llc Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
KR20040103972A (ko) 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
BR0316680A (pt) * 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
CN101014600A (zh) * 2004-09-21 2007-08-08 霍夫曼-拉罗奇有限公司 用作蛋白激酶抑制剂的6-(2-烷基-苯基)-吡啶并[2,3-d]嘧啶类
UY29439A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
UY29440A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
EP1865959A2 (en) 2005-03-25 2007-12-19 Glaxo Group Limited Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
WO2006110298A2 (en) 2005-03-25 2006-10-19 Glaxo Group Limited 8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
WO2007009911A1 (en) * 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS
ATE482958T1 (de) * 2005-08-09 2010-10-15 Irm Llc Verbindungen und zusammensetzungen als proteinkinaseinhibitoren
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
WO2010063352A1 (en) * 2008-12-01 2010-06-10 Merck Patent Gmbh 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
WO2014151682A1 (en) 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
HUT76853A (en) * 1994-11-14 1997-12-29 Warner Lambert Co 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation and pharmaceutical compositions containing the same
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
AU763839B2 (en) * 1998-05-26 2003-07-31 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation

Also Published As

Publication number Publication date
CA2397961C (en) 2008-08-26
CZ20022475A3 (cs) 2003-03-12
JP4047010B2 (ja) 2008-02-13
NO20023527D0 (no) 2002-07-24
IS6443A (is) 2002-06-25
BG106850A (bg) 2003-02-28
CO5261549A1 (es) 2003-03-31
MXPA02007221A (es) 2002-11-29
ZA200205879B (en) 2003-09-29
MA26868A1 (fr) 2004-12-20
CR6706A (es) 2005-04-04
NO20023527L (no) 2002-09-10
TNSN01014A1 (fr) 2005-11-10
BR0107751A (pt) 2002-11-12
PA8510701A1 (es) 2002-12-11
HUP0204141A3 (en) 2005-03-29
OA12161A (en) 2006-05-08
HN2001000013A (es) 2001-06-18
EA200200643A1 (ru) 2002-12-26
PE20011066A1 (es) 2001-10-22
AU2542501A (en) 2001-08-07
SK10632002A3 (sk) 2003-06-03
CA2397961A1 (en) 2001-08-02
HUP0204141A2 (hu) 2003-04-28
KR20020065939A (ko) 2002-08-14
EE200200405A (et) 2003-12-15
AR030044A1 (es) 2003-08-13
IL150545A0 (en) 2003-02-12
CN1395578A (zh) 2003-02-05
EP1254137A1 (en) 2002-11-06
PL356802A1 (en) 2004-07-12
JP2003523357A (ja) 2003-08-05
WO2001055147A1 (en) 2001-08-02
DZ3266A1 (fr) 2001-08-02
AP2002002586A0 (en) 2002-09-30
YU50402A (sh) 2005-11-28
GT200100016A (es) 2001-10-19

Similar Documents

Publication Publication Date Title
SV2002000294A (es) Pirido [2,3-d] pirimidin-2,7-diaminas inhibidores de cinasas ref. pca 84-01-ca/20131/bb
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.
CY1118096T1 (el) Ρυθμιστες υποδοχεα οπιοειδους
PE20040914A1 (es) Derivados de pirrolopirimidina como inhibidores de tirosina quinasas
ATE554087T1 (de) Neue kinaseinhibitoren
DK1333833T3 (da) Ny trisubstitueret 8H-pyridol[2,3-d]pyrimidin-7-on-forbindelse til behandling af CSBP/RK/p38-kinnasemedierede sygdomme
ECSP066336A (es) Derivados de 3-amino croman y 2-amino tetralin
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
SG146657A1 (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
IL177291A0 (en) Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
ECSP077992A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms
CL2011001129A1 (es) Compuestos derivados de alquilciclohexileteres de dihidro-tetraazbenzoazulenos, antagonistas del receptor de la v1a; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de la dismenorrea, disfuncion sexual masculina o femenina, hipertension, ansiedad, esquizofrenia, entre otros.
CR9649A (es) Aminopirimidinas como modulares de cinasa
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
AR056197A1 (es) Derivados de 7-metilimidazol[1,2-a]piridin-6-il-8-metil-nonamidas como inhibidores de la renina, composciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de la hipertension arterial
EP1233951A4 (en) 3,4-DIHYDRO (1H) CHINAZOLIN-2-ON COMPOUNDS AS CSBP / P38 KINASE INHIBITORS
BRPI0417520A (pt) 1h-pirrolo[3,2-b, 3,2-c, e 2,3-c]piridina-2-carboxamidas substituìdas e análogos relatados como inibidores de caseìna cinase i-epsilon
DE60023025D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
UA95230C2 (ru) ЗАМЕЩЕННЫЕ ТЕТРАГИДРОПИРИМИДО[4,5-d]ПИРИМИДИНЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИХ, И ИХ ПРИМЕНЕНИЕ
EA201000618A1 (ru) 5-цианотиенопиридины для лечения опухолей
PL374019A1 (en) Benzoxazine derivatives as 5-ht6 modulators and uses thereof
ATE370952T1 (de) Neue verbindungen
EP1235814A4 (en) 3,4-DIHYDRO- (1H) QUINAZOLINE-2-ONE COMPOUNDS FOR USE AS CSBP / p38 KINASE INHIBITORS
EA200600688A1 (ru) Арилинденпиридины и арилинденпиримидины и их применение в качестве антагонистов аденозинового рецептора а2а

Legal Events

Date Code Title Description
FD Lapse